ADMA Biologics Valuation
| ADMA Stock | USD 15.94 0.55 3.34% |
At this time, the firm appears to be undervalued. ADMA Biologics shows a prevailing Real Value of $20.01 per share. The current price of the firm is $15.94. Our model approximates the value of ADMA Biologics from examining the firm fundamentals such as Operating Margin of 0.38 %, return on equity of 0.63, and Profit Margin of 0.43 % as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ADMA Biologics' valuation include:
Price Book 9.1018 | Enterprise Value | Enterprise Value Ebitda 22.9263 | Price Sales 7.7857 | Forward PE 28.9855 |
Undervalued
Today
Please note that ADMA Biologics' price fluctuation is not too volatile at this time. Calculation of the real value of ADMA Biologics is based on 3 months time horizon. Increasing ADMA Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ADMA Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ADMA Stock. However, ADMA Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.94 | Real 20.01 | Target 25.67 | Hype 15.89 | Naive 15.99 |
The real value of ADMA Stock, also known as its intrinsic value, is the underlying worth of ADMA Biologics Company, which is reflected in its stock price. It is based on ADMA Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ADMA Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ADMA Biologics helps investors to forecast how ADMA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ADMA Biologics more accurately as focusing exclusively on ADMA Biologics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ADMA Biologics' intrinsic value based on its ongoing forecasts of ADMA Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ADMA Biologics' closest peers. If more than one evaluation category is relevant for ADMA Biologics we suggest using both methods to arrive at a better estimate.
ADMA Biologics Cash |
|
ADMA Revenue by Product
ADMA Biologics Total Value Analysis
ADMA Biologics is presently expected to have valuation of 3.95 B with market capitalization of 3.8 B, debt of 82.12 M, and cash on hands of 52.42 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ADMA Biologics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.95 B | 3.8 B | 82.12 M | 52.42 M |
ADMA Biologics Investor Information
About 94.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Based on the key indicators related to ADMA Biologics' liquidity, profitability, solvency, and operating efficiency, ADMA Biologics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.ADMA Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ADMA Biologics has an asset utilization ratio of 87.27 percent. This suggests that the Company is making $0.87 for each dollar of assets. An increasing asset utilization means that ADMA Biologics is more efficient with each dollar of assets it utilizes for everyday operations.ADMA Biologics Profitability Analysis
Based on ADMA Biologics' profitability indicators, ADMA Biologics is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess ADMA Biologics' ability to earn profits and add value for shareholders.Net Income | First Reported 2006-09-30 | Previous Quarter 34.2 M | Current Value 36.4 M | Quarterly Volatility 19 M |
For ADMA Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ADMA Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ADMA Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ADMA Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ADMA Biologics over time as well as its relative position and ranking within its peers.
ADMA Biologics Earnings per Share Projection vs Actual
By analyzing ADMA Biologics' earnings estimates, investors can diagnose different trends across ADMA Biologics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for ADMA Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.ADMA Biologics Ownership Allocation
ADMA Biologics holds a total of 238 Million outstanding shares. The majority of ADMA Biologics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ADMA Biologics to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in ADMA Biologics. Please pay attention to any change in the institutional holdings of ADMA Biologics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.ADMA Biologics Profitability Analysis
The company reported the previous year's revenue of 426.45 M. Net Income was 197.67 M with profit before overhead, payroll, taxes, and interest of 267.28 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ADMA Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ADMA Biologics and how it compares across the competition.
About ADMA Biologics Valuation
The stock valuation mechanism determines ADMA Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of ADMA Biologics. We calculate exposure to ADMA Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ADMA Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 252.5 M | 265.1 M | |
| Pretax Profit Margin | 0.27 | 0.28 | |
| Operating Profit Margin | 0.29 | 0.31 | |
| Net Profit Margin | 0.42 | 0.44 | |
| Gross Profit Margin | 0.59 | 0.62 |
ADMA Biologics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 243.3 M | |
| Forward Price Earnings | 28.9855 |
ADMA Biologics Current Valuation Indicators
Valuation refers to the process of determining the present value of ADMA Biologics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ADMA we look at many different elements of the entity such as ADMA's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ADMA Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ADMA Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ADMA Biologics' worth.Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |